Lai et al., 2014 - Google Patents
Production of a neutralizing antibody against envelope protein of dengue virus type 2 using the linear array epitope techniqueLai et al., 2014
View PDF- Document ID
- 4197977019789343709
- Author
- Lai P
- Hsu C
- Wang S
- Lee J
- Tseng M
- Hwang J
- Ji W
- Chen H
- Publication year
- Publication venue
- Journal of General Virology
External Links
Snippet
Dengue virus (DENV; genus Flavivirus) contains a positive-stranded RNA genome. Binding of DENV to host cells is mediated through domain III of the viral envelope protein. Many therapeutic mAbs against domain III have been generated and characterized because of its …
- 102000033180 ERVK-6 0 title abstract description 45
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA Viruses positive-sense
- C12N2770/00011—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA Viruses positive-sense ssRNA Viruses positive-sense
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/569—Immunoassay; Biospecific binding assay for micro-organisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses, e.g. hepatitis E virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Carpio et al. | Flavivirus NS1 and its potential in vaccine development | |
Sukupolvi-Petty et al. | Type-and subcomplex-specific neutralizing antibodies against domain III of dengue virus type 2 envelope protein recognize adjacent epitopes | |
Scaturro et al. | Dengue virus non-structural protein 1 modulates infectious particle production via interaction with the structural proteins | |
Goncalvez et al. | Epitope determinants of a chimpanzee Fab antibody that efficiently cross-neutralizes dengue type 1 and type 2 viruses map to inside and in close proximity to fusion loop of the dengue type 2 virus envelope glycoprotein | |
Du et al. | The spike protein of SARS-CoV—a target for vaccine and therapeutic development | |
Li et al. | Dengue virus envelope domain III immunization elicits predominantly cross-reactive, poorly neutralizing antibodies localized to the AB loop: implications for dengue vaccine design | |
Lai et al. | Epitope determinants of a chimpanzee dengue virus type 4 (DENV-4)-neutralizing antibody and protection against DENV-4 challenge in mice and rhesus monkeys by passively transferred humanized antibody | |
Goncalvez et al. | Humanized monoclonal antibodies derived from chimpanzee Fabs protect against Japanese encephalitis virus in vitro and in vivo | |
Azevedo et al. | DNA vaccines against dengue virus type 2 based on truncate envelope protein or its domain III | |
Zheng et al. | A toggle switch controls the low pH-triggered rearrangement and maturation of the dengue virus envelope proteins | |
Clark et al. | In situ reactions of monoclonal antibodies with a viable mutant of Murray Valley encephalitis virus reveal an absence of dimeric NS1 protein | |
Yoshii et al. | A conserved region in the prM protein is a critical determinant in the assembly of flavivirus particles | |
Luo et al. | Identification of a novel infection-enhancing epitope on dengue prM using a dengue cross-reacting monoclonal antibody | |
Chiou et al. | Mutation analysis of the cross-reactive epitopes of Japanese encephalitis virus envelope glycoprotein | |
Lisova et al. | Mapping to completeness and transplantation of a group-specific, discontinuous, neutralizing epitope in the envelope protein of dengue virus | |
Rockstroh et al. | Recombinant envelope-proteins with mutations in the conserved fusion loop allow specific serological diagnosis of dengue-infections | |
Han et al. | Immunization with truncated envelope protein of Zika virus induces protective immune response in mice | |
Crill et al. | A detailed mutagenesis study of flavivirus cross-reactive epitopes using West Nile virus-like particles | |
Chidumayo et al. | Evaluation of the European tick‐borne encephalitis vaccine against Omsk hemorrhagic fever virus | |
Tang et al. | Generation of monoclonal antibodies against Dengue virus type 4 and identification of enhancing epitopes on envelope protein | |
Lam et al. | A potent neutralizing IgM mAb targeting the N218 epitope on E2 protein protects against Chikungunya virus pathogenesis | |
Chattopadhyay et al. | Development and characterization of monoclonal antibody against non-structural protein-2 of Chikungunya virus and its application | |
Falconar | Monoclonal antibodies that bind to common epitopes on the dengue virus type 2 nonstructural-1 and envelope glycoproteins display weak neutralizing activity and differentiated responses to virulent strains: implications for pathogenesis and vaccines | |
Sun et al. | Comprehensive mapping of West Nile virus (WNV)-and Japanese encephalitis virus serocomplex-specific linear B-cell epitopes from WNV non-structural protein 1 | |
Setoh et al. | Identification of residues in West Nile virus pre-membrane protein that influence viral particle secretion and virulence |